Samsung’s bet on biotech is test for heir apparent

CMO, 의약품 파운드리, Samsung BioLogics, Samsung Bioepis,

Samsung BioLogics is following this blueprint closely. Its second plant, built on reclaimed land near South Korea’s main airport, will have a capacity of 150,000 liters–five times the size of its first plant. It will start ramping up next year as it seeks clearance from the U.S. Food and Drug Administration. And the company’s third plant will be even bigger, with 180,000 liters of capacity.

 

소스: Samsung’s bet on biotech is test for heir apparent

댓글 남기기

이메일은 공개되지 않습니다. 필수 입력창은 * 로 표시되어 있습니다